In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia - Endpoints News
endpts.comSubmitted by endpointsnews6292 in news
Vertex and CRISPR Therapeutics have won the first-ever approval for a therapy created with CRISPR gene editing, as the UK drug regulator MHRA greenlights their treatment for two blood disorders. The therapy previously known as exa-cel will now be branded Casg…